Last reviewed · How we verify
NCT06212245
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Phase 4 trial testing Inebilizumab in Neuromyelitis Optica Spectrum Disorders in 33 participants. Status unknown.
25 December 2024
Quick facts
| Lead sponsor | Hansoh BioMedical R&D Company |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 25 February 2024 |
| Primary completion | 25 December 2024 |
| Estimated completion | 25 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Inebilizumab (INEBILIZUMAB) — full drug profile →
Conditions studied
- Neuromyelitis Optica Spectrum Disorders — all drugs for Neuromyelitis Optica Spectrum Disorders →
Sponsor
Hansoh BioMedical R&D Company — full company profile →
Who can join
18 and older, any sex, with Neuromyelitis Optica Spectrum Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in the treatment of neuromyelitis optic spectrum disorder.
Yang X, Zhang S, Feng J, Qin X. · · 2025 · cited 1× · PMID 40291752 · DOI 10.1177/17562864251328276
Verify or expand the search:
- PubMed search for NCT06212245
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Inebilizumab
Trials testing the same drug.
- NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
- NCT07222553 — Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Particip · Phase 2 · not yet recruiting
- NCT06570798 — A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases · Phase 2 · recruiting
- NCT05891379 — Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders · recruiting
- NCT06180278 — Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) · Phase 4 · active not recruiting
Other recruiting trials for Neuromyelitis Optica Spectrum Disorders
Currently open trials in the same condition.
- NCT07202494 — Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and · recruiting
- NCT06763848 — Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder · NA · recruiting
- NCT06620809 — The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders · Phase 1 · recruiting
- NCT06865274 — Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte My · NA · recruiting
- NCT06724809 — Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD · Phase 3 · active not recruiting
Other Hansoh BioMedical R&D Company trials
Trials by the same sponsor.
- NCT07464327 — A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With A · Phase 3 · not yet recruiting
- NCT07462923 — HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma · Phase 1 · recruiting
- NCT07283367 — A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. · Phase 1, PHASE2 · not yet recruiting
- NCT07186452 — Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06844799 — A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06212245 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hansoh BioMedical R&D Company
- Last refreshed: 18 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06212245.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing